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Translation of androgen receptor (AR) cRNA in a reticulocyte
lysate and subsequent analysis of the translation products by
SDS/PAGE showed a protein with an apparent molecular mass
of 108 kDa. Scatchard-plot analysis revealed a single binding
component with high affinity for R1881 (Kd = 0.3 nM). All AR
molecules synthesized specifically bound steroid. No evidence for
AR phosphorylation during in vitro synthesis was found. When
AR was labelled with [3H]R1881 and analysed on sucrose-
density gradients, a complex of approx. 6 S was observed. The
complex was shifted to a higher sedimentation coefficient after
incubation with a monoclonal AR antibody directed against an
epitope in the DNA-binding domain. In the presence as well as
INTRODUCTION
The androgen receptor (AR) can be isolated in the cytosol of
target cell extracts as a large non-activated (i.e. non-DNA-
binding) 8 S complex. Recently, it was shown that this complex
contains the 90 kDa heat-shock protein (hsp90), the 70 kDa
heat-shock protein (hsp70) and a 56-59 kDa protein [1]. This
large multiprotein non-activated complex dissociates on hormone
binding, thereby revealing the DNA-binding domain of the
receptor [2]. The AR then binds to specific enhancer sequences
referred to as hormone-responsive elements present in the 5'
flanking region of target genes and is supposed to regulate
transcription via protein-DNA interactions and by interactions
with other transcription factors [3].
The primary structure of the AR has been elucidated, and the
domains responsible for ligand binding, DNA binding, nuclear
localization and transcriptional modulation have been identified
[4,5]. AR belongs to a superfamily of nuclear proteins including
the receptors for the other classes of steroid hormones, thyroid
hormone, vitamin D and retinoids [6-8].
It is important to understand the intracellular dynamics of
steroid receptor proteins and the factors that control their
steroid-binding capacity and DNA-binding activity. Expression
of AR in a suitable host system could facilitate our ability to
study the physical properties oftheAR protein and the molecular
basis of androgen action. A variety of systems has been used for
the (over)expression of steroid receptors. The full-length pro-
gesterone and glucocorticoid receptors have been expressed in
yeast, using Saccharomyces cerevisiae as a host system [9,10].
Segments of the glucocorticoid, progesterone and androgen
receptor cDNAs were expressed in Escherichia coli and were
found to exhibit similar biological activities when compared with
the absence of hormone, AR molecules were able to bind to
DNA-cellulose without an activation step. Gel retardation assays
revealed that the AR forms complexes with a DNA element
containing glucocorticoid-responsive element/androgen-respon-
sive element sequences. Receptor-DNA interactions were stabi-
lized by different polyclonal antibodies directed against either the
N- or C-terminal part of the AR and were abolished by an
antibody directed against the DNA-binding domain of the
receptor. In conclusion, translation of AR cRNA in vitro yields
an activated AR protein which binds steroid with high affinity. It
is proposed that AR antibodies enhance AR-DNA binding by
stabilizing AR dimers when bound to DNA.
the native receptors [11-14]. Attempts to produce full-length AR
protein by expressing human AR in E. coli, yeast or insect cells
have been problematical, resulting, in general, in the synthesis of
insoluble proteins [13-16].
Rabbit reticulocyte lysates contain quite large amounts of
several hsps such as hsp90 and hsp70 and are useful for the study
of steroid-receptor complex formation with hsps as well as for
the study of requirements for steroid binding and interaction
with DNA [17-19].
In the present paper, the in vitro synthesis of the full-length
human AR is described as well as the analysis of the steroid-
binding properties, hydrodynamic characteristics and specific
binding to an androgen-responsive element (ARE).
MATERIALS AND METHODS
Materials
[35S]Methionine (specific radioactivity > 1000 Ci/mmol) and
[y-32P]ATP were obtained from Amersham (Little Chalfont,
Bucks., U.K.). The synthetic androgen 17/J-hydroxy-17a-
[3H]methyl-4,9,11-oestratrien-3-one ([3H]R1881; specific radio-
activity approx. 87 Ci/mmol) and unlabelled R1881 were
purchased from NEN-Dupont de Nemours ('s-Hertogenbosch,
The Netherlands).
Recombinant RNasin and rabbit reticulocyte lysate were
obtained from Promega Biotech (Madison, WI, U.S.A.). RNA
transcription kit containing T7 and T3 RNA polymerase
(EC 2.7.7.6) and pBluescript cloning vector were obtained from
Stratagene (La Jolla, CA, U.S.A.).
The antisera spO60 (epitope amino acid residues 201-222),
spO66 (epitope amino acid residues 899-917), spl97 (epitope
amino acid residues 1-20) and spO63 (epitope amino acid residues
Abbreviations used: AR, androgen receptor; hsp, heat-shock protein; GRE, glucocorticoid-responsive element; ARE, androgen-responsive element;
ERE, oestrogen-responsive element; R1881, 17,8-hydroxy-17a-methyl-4,9,11-oestratrien-3-one; DTT, dithiothreitol.
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593-612) were prepared by previously published procedures
[2,20,21]. The antisera spl97, sp060 and sp063 contain high-titre
AR antibodies, as shown by immunoprecipitation and Western
blotting [20-22]. The antiserum sp066 recognizes the 110-
112 kDa AR on Western blots [20].
Mouse monoclonal antibody F 39.4.1 (designated F39) was
prepared against the N-terminal domain ofthe androgen receptor
[20]. Mouse monoclonal antibody F 52.24.4 (designated F52)
was prepared against the C-terminal part of the DNA-binding
domain of the androgen receptor [2].
Calf-thymus DNA-cellulose (4 mg of DNA/g of cellulose)
was obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
All other chemicals and reagents were purchased from Merck
(Darmstadt, Germany).
In vitro transcription and translation
The coding sequences of human AR cDNA were excised from
the expression vector pSVARO [23] at the Sall (EC 3.1.23.37)
sites and inserted into the dual promotor (T7/T3) vector pBlue-
script II-KS (Stratagene) and was designated pARO. For
transcription the vector (1 ,Cg) was linearized with- XhoI
(EC 3.1.23.42) (sense cRNA) or BamHI (EC 3.1.23.6) (antisense
cRNA) and transcribed in vitro with either T7 RNA polymerase
(sense cRNA) or T3 RNA polymerase according to manu-
facturers' instructions.
Translation reactions (50 pu) in rabbit reticulocyte lysates were
carried out as recommended by the supplier. Each reaction
mixture included 35 pl of rabbit reticulocyte lysate, 40 units of
RNasin, 10 ,tM ZnCl2, 1 ,ul of 1 mM amino acid mixture without
methionine, 45 #Ci of [35S]methionine and 1-2 /ug of human AR
RNA transcript. The samples were incubated for 1 h at 30 °C
and thereafter stored at -20 °C or used directly. In order to
measure the amount of [35S]methionine incorporated, samples
were subjected to SDS/PAGE (7 % gels), sample lanes were cut
in 2 mm slices and counted in liquid-scintillation cocktail for 35S
radioactivity.
Electrophoresis, electrobloffing and autoradiography
These were carried out according to previously described pro-
cedures [24].
Metaboiic labelilng of Iymph node carcinoma of the prostate
(LNCaP) cells with (US]methionine
For labelling studies, 6 x 107 LNCaP cells [24] were incubated for
60 min at 37 °C with 20,Ci/ml [35S]methionine (total 100 ,Ci)
in methionine-free RPMI 1640 medium. Cell lysis and AR
immunopurification were by published procedures [24].
Steroid binding
Translation reaction mixtures prepared with non-radioactive
methionine were diluted four times with buffer A [40 mM
Tris/HCl, pH 7.4, 1 mM EDTA, 10% (w/v) glycerol, 10 mM
dithiothreitol (DTT), 10 mM Na2MoO4, 50 mM NaF) and
incubated for 3 h at 4°C with 0.1-10 nM [3H]R1881 in the
presence or absence of a 100-fold excess of unlabelled R1881.
Thereafter, bound and unbound steroid were separated with
Sucrose-density-gradient centritugation
Sucrose density gradients t10-30% (w/v) sucrose] were prepared
in buffer A with or without 0.4 M NaCl. Reticulocyte lysate
containing translation products (50 pAl) was mixed with 50 ,u of
buffer A and incubated with 10 nM [3H]R1881 in the presence or
absence of a 100-fold excess of unlabelled R1881 for 2 h at 4 °C.
When appropriate, ascitic fluid (1 #1l) with monoclonal antibody
F39 or F52 or a non-specific antibody was added. Samples of
40 ,1 were loaded on to the gradients. The gradients were run for
20 h at 50000 rev./min in a SW-60 rotor (Beckman) at 4 °C in a
Beckman L70 centrifuge. 14C-labelled BSA (4.6 S) and [14C]-
aldolase (7.9 S) were used as internal markers. Fractions of the
gradients were collected from the bottom and assayed for
radioactivity.
When [35S]methionine was used to label AR protein during in
vitro synthesis, samples of the fractions were incubated for 1 h at
37 °C with 1 ml of 1 M NaOH/2% (v/v) H202. Proteins were
then precipitated by the addition of 3 ml of 16% (w/v) trichloro-
acetic acid/2% (w/v) casamino acids, at 4°C. After centri-
fugation (15 min at 3000 g), pellets were washed with 0.5 ml of
5% trichloroacetic acid and thereafter solubilized in 1 M NaOH.
After neutralization with conc. HCI, samples were analysed for
35S radioactivity by liquid-scintillation counting.
DNA-cellulose chromatography
Reticulocyte lysate containing [35S]methionine-labelled trans-
lation products or non-radioactive receptor was diluted five
times with TEDG buffer [40 mM Tris/HCl, pH 7.4, 1 mM
EDTA, 10 mM DTT and 10 % (w/v) glycerol] and incubated for
2 h at 4 °C with buffer only or 10 nM [3H]R1881 respectively.
A DNA-cellulose suspension (12.5%, w/v) of 750,u1 was
added to 300 ,u1 of diluted lysate and incubated for 60-120 min at
4 °C with constant mixing. The mixture was poured into a small
column and washed with TEDG buffer until no free radiolabelled
steroid could be monitored. Bound 3H-labelled steroid was
eluted with TEDG buffer containing 1 M NaCl; fractions of
100 jl were collected. Alternatively, bound 3H-labelled steroid
was eluted with a gradient ranging from 50 to 300 mM NaCl in
TEDG buffer. Conductivity was measured with a Philips PW-
9505 conductivity meter equipped with a PW-9513 measuring
cell (constant 1.62). Conductivity was compared with a standard
curve of known NaCl concentration in the appropriate buffer.
When [35S]methionine-labelled lysates were used, fractions of the
eluate were run on an SDS/7% polyacrylamide gel and blotted
to nitrocellulose. After autoradiography, the blot was sliced and
the slices were counted after solubilization in Filtercount cocktail
(Packard Company).
Gel retardation assay
A glucocorticoid-responsive element (GRE) consensus oligo-
nucleotide sequence 5'-TCGACTGTACAGGATGTTCTAGC-
TACT-3' was obtained from Promega. Double-stranded oligo-
nucleotide was labelled using T4 polynucleotide kinase with
[y-32P]ATP to a specific radioactivity of S x 108 d.p.m./,g.
The binding reaction mixture (15 ul) contained typically 2 ,ul
of reticulocyte lysate (1.5-2 fmol of AR protein) with 2 ,g of
poly(dI-dC) poly(dI-dC) in buffer [10 mM Hepes, pH 7.9,
60 mM KCl, 1 mM DTT, 1 mM EDTA, 4% Ficoll] and 0.2 ng
(12 fmol) of labelled GRE. After incubation for 30 min on ice,
the protein-bound DNA complexes were separated from free
probe on a 4% polyacrylamide gel (45:1) run in 0.25 x TBE
(1 x TBE = 50 mM Tris base, 50 mM boric acid, 1 mM EDTA,
pH 8.6) for 1.5-2 h at room temperature. Gels were fixed fordextran-coated charcoal.
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15 min in 10% acetic acid/1O % methanol, dried and auto-
radiographed.
In experiments with AR antibodies, 0.1 Js1 portions of antisera
were preincubated for 1 h at 4 °C with reticulocyte lysates before
addition of reaction mixture.
Besides unlabelled GRE, two other oligonucleotides were used
for competition experiments: one containing an ARE from the
prostate-specific antigen promotor (position -170 to -156)
sequence 5'-GATCCAGCTAGCACTTGCTGTTCTGCAAG-
3' according to Riegman et al. [25] and one containing an
oestrogen-responsive element (ERE) [26] from the apo-very-low-
density lipoprotein II promotor region (position - 165 to - 177),
sequence 5'-GATCCTCAGGTCAGACTGACCTTCG-3',
kindly provided by Dr. G. AB, Department of Biochemistry,
University of Groningen, The Netherlands.
Site-directed mutagenesis
The AR mutant in which Cys-602 and Cys-605 were mutated to
Ser residues was constructed by site-directed mutagenesis using
PCR DNA-amplification techniques on pSVARO [23]. The
primer used to introduce the mutation was 5'-CCGAAGGA-
AGAATTCTCCATCTTCTCGTC-3'. From the resulting
mutant plasmid pSVAR65, a 700 bp BstEII-AspI fragment was
excised and exchanged with pARO. The mutant transcription
vector was designated pAR65.
RESULTS
Characterizaton of AR synthesized In rabbit reticulocyte lysate
The rabbit reticulocyte lysate was programmed for protein
synthesis with in vitro transcribed human AR cRNA in the
presence of [35S]methionine. Analysis of the translation products
by SDS/PAGE showed a predominant band with an apparent
molecular mass of 108 kDa (Figure 1). For comparison, the
result of a labelling experiment with LNCaP cells is shown. The
AR from LNCaP cells migrates as a closely spaced doublet of
110-112 kDa on SDS/PAGE as described previously [24]. This
heterogeneity reflects differential AR phosphorylation [22,24].
From the results shown in Figure 1, it is clear that the AR in
reticulocyte lysate is synthesized as a single 108 kDa protein,
indicating that it is not phosphorylated during in vitro synthesis
in the same way as during synthesis in LNCaP cells. Also, after
incubation of reticulocyte lysates with [y-32P]ATP during AR
synthesis, it was not possible to detect phosphorylated AR
after immunopurification, whereas several other unknown
phosphorylated proteins could be detected in the lysate (result
not shown).
In order to analyse the steroid-binding properties of AR
synthesized in vitro, the reticulocyte lysate was incubated at 4 °C
for 3 h with increasing concentrations (0.1-10 nM) of [3H]R1881
in the presence or absence ofa 100-fold molar excess ofunlabelled
R1881. Linear transformation of saturation data revealed a
uniform non-interacting population of binding sites for R1881
with a maximum binding capacity of 480 fmol/ml and a dis-
sociation constant of 0.3 nM (Figure 2).
In parallel experiments, the amount of synthesized AR protein
was determined by incorporation of[35S]methionine. The amount
was estimated from methionine pool size (5,uM according to the
manufacturer), the amount of [35S]methionine incorporated and
the number of methionine residues in the receptor molecule. It is,
calculated that each of the intact (108 kDa) AR proteins binds
1.0+0.1 (n = 2) molecules of R1881 at a saturating ligand
concentration.
When the AR was labelled with [3H]R1881 and analysed on
sucrose density gradients, a single peak of specifically bound
radioactivity (Figure 3a) was observed. The sedimentation coeffi-
cient of this complex was approx. 6 S. In the presence of high salt
(0.4 M NaCl), the sedimentation coefficient ofAR shifted to 4 S.
When the AR was synthesized in the presence of [35S]methionine,
the sedimentation coefficient was also approx. 6 S, and shifted to
4 S in the presence of high salt (results not shown).
The monoclonal antibody F39 is directed against an epitope in
the N-terminus of AR (amino acid residues 301-320) and was
able to shift the 6 S AR complex to a sedimentation coefficient of
about 10 S. Also, the monoclonal antibody F52 which is directed
against an epitope in the DNA-binding domain (amino acid
residues 593-612) was able to shift the 6 S complex to a higher
sedimentation coefficient (8 S) (Figure 3b). This indicates that
the DNA-binding domain is exposed in the 6 S AR complex. A
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Figure 1 Synthesis of AR in rabbit reticulocyte iysate and In LNCaP cells
Transcription of pARO was carried out as described in the Materials and methods section.
Translation was performed in the presence of [35S]methionine, and total lysates were analysed
by SDS/PAGE and autoradiography. For comparison, LNCaP cells preincubated for 60 min in
methionine-free medium were incubated for 60 min with [35S]methionine. Subsequently, AR was
immunoprecipitated with F39 monoclonal antibody and analysed by SDS/PAGE. Lane 1,
immunoprecipitate of LNCaP cells; lane 2, reticulocyte lysate (1 ,Fl) with sense cRNA; lane 3,
reticulocyte lysate (1 ,zl) with antisense cRNA. Molecular-mass markers (kDa) are indicated on
the left.
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Figure 2 Scatchard plot of [H]R1881 binding to AR synthesized In vitro
Reticulocyte lysate was incubated with six concentrations of [3H]R1881 ranging from 0.1 to
10 nM. Parallel tubes contained an additional 1 00-fold excess of non-radioactive Rl 881. Bound
and free ligand were separated using a dextran-coated charcoal assay. The Kd (0.3 nM) was
calculated from the slope of the line, and the number of binding sites was extrapolated from
theintercept on the abscissa (B,n,x = 480 fmof/ml of translation mixture). The aspecific binding
was less than 5% of total binding.
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Figure 3 Sucrose-density-gradient profiles of human
in vitro
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Figure 5 Binding of AR synthesized in vitro to a GRE
Lysates (2 ,u) with AR protein (lanes 1-8) or without AR protein (lanes 9-10) were incubated
with a 32P-labelled GRE, and protein-DNA complexes were separated from free DNA by non-
denaturing gel electrophoresis as described in the Materials and methods section. Lanes 1 and
9, preincubation of lysate with normal rabbit serum; lanes 2-8 and 10, preincubation with spl 97
(0.1 1ul) antiserum. In all lanes the same amount of 32P-GRE was added in the absence (lanes
1, 2, 9, 10) or presence (lanes 3-8) of unlabelled GRE. The excess unlabelled GRE was 2-fold
(lane 3), 5-fold (lane 4), 10-fold (lane 5), 20-fold (lane 6), 50-fold (lane 7) and 100-fold (lane
8). The AR-GRE complex is indicated by an arrow.
DNA-binding properties of human AR synthesized in vitro
Interaction of receptors with DNA-cellulose is generally used as
a measure of activation to the DNA-binding state of steroid
receptors. Human AR synthesized in vitro was tested for binding
ability to DNA-cellulose after being labelled with [3H]R1881 for
2 h at 4 'C. Figure 4(a) established that AR synthesized in vitro
is retained on a DNA-cellulose column. The AR was also eluted
from the DNA-cellulose with a linear salt gradient and was
obtained in the fractions containing 120 mM NaCl (n = 2)
(Figure 4b). Experiments with 35S-labelled AR incubated with
DNA-cellulose in the absence of R1881 gave similar results. So
it appears that the presence of hormone is not essential for AR
to be able to bind to DNA-cellulose.
In further experiments, we have tested the ability of the AR
AR was synthesized and incubated with [3H]R1 881 as described in the Materials and methods
section. (a) The lysate (50 #sl) was incubated for 2 h with [3H]R1881 alone (0) or [3H]R1 881
and a 100-fold excess of unlabelled R1881 (A) and analysed by sucrose-density-gradient
centrifugation without salt as described. Another sample (20 U1l of lysate) was loaded on a
10-30% sucrose density gradient with 0.4 M NaCI (U). BSA (4.6 S) and aldolase (7.9 S) were
used as sedimentation markers on a parallel gradient. (b) The lysate (50 ,sl) was incubated for
2 h with either 1 ,lI of ascitic fluid containing the androgen receptor antibody F39 (0) or F52
(A) or 1 Isl of ascitic fluid containing a non-specific antibody (M). Samples (20 ,ul of lysate)
were run on 10-30% sucrose density gradients without added salt as described in the Materials
and methods section.
control sample of mouse ascites containing monoclonal anti-
bodies against the Fos oncoprotein was not able to change the
sedimentation coefficient of the 6 S AR complex (Figure 3b).
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Figure 4 Elution from DNA-cellulose of AR synthesized in vitro
Reticulocyte lysates containing translational products of sense (0) or antisense (A) AR cRNA (a), or sense (-) AR cRNA (b) were diluted five times with TEDG buffer, pH 7.4, and incubated
with [3H]R1881 (10 nM for 2 h at 4 °C). A DNA-cellulose suspension was added and incubation was continued for 60 min at 4 0C with mixing. The suspension was poured in a column and washed
with TEDG buffer until essentially no free [3H]R1881 was detected. Bound AR was eluted with either TEDG buffer containing 1 M NaCI starting at fraction 30 (a) or a gradient ranging from 50
to 300 mM NaCI (A) in TEDG buffer (b).
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Figure 6 Binding of AR synthesized in vitro to nP-Iabelled GRE: influence
of preincubatlon with ligand or salt
(a) Reticulocyte lysate was preincubated with 10 nM R1881 (lanes 2 and 4) or without Rl 881
(lanes 1 and 3) for 60 min at 4 °C. Thereafter lysates were incubated with spl97 antiserum
(lanes 3 and 4) or with normal rabbit serum (lanes 1 and 2). Incubation with 32P-labelled GRE
and further analysis was as in Figure 5. (b) Reticulocyte lysates containing AR protein were
incubated with NaCI (200 mM) for 60 min at 4 °C (lanes 2 and 3) or with buffer only (lane
1). Thereafter lysates were incubated with spl97 antiserum (lane 3) or normal rabbit serum
(lanes 1 and 2) followed by incubation with 32P-labelled GRE and further analysis as described.
The AR-GRE complex is indicated by an arrow.
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Figure 7 DNA-binding speciflcity of AR synthesized In vitr
Lysate containing AR (2 cFl) was used in an incubation with 32P-labelled GRE alone (lane 1)
or in the presence of various competitors (lanes 2-10). In all lanes (1-10) the spl 97 antiserum
(0.1 ul) was also added. Protein-DNA complexes were separated from free DNA by non-
denaturing electrophoresis as described in the Materials and methods section. Competitors
used were: 1 0-fold ARE (lane 2), 50-fold ARE (lane 3), 1 00-fold ARE (lane 4), 1 0-fold ERE (lane
5), 50-fold ERE (lane 6), 100-fold ERE (lane 7), 10-fold GRE (lane 8), 50-fold GRE (lane 9) and
100-fold GRE (lane 10). The AR-GRE complex is indicated by an arrow. See the Materials and
methods section for sequences of competitors.
synthesized in vitro to interact with specific DNA sequences. For
these experiments, a consensus GRE was used, which has
previously been shown to confer androgen-responsiveness to a
reporter gene [4]. Reticulocyte lysates containing AR protein,
but not lysates programmed with antisense AR cRNA, were able
to interact with a 27-mer oligonucleotide containing the above-
mentioned GRE, as shown by gel mobility-shift assays. However,
the complexes observed were very faint. Incubation with an
antiserum against AR, recognizing the first 20 amino acids
(spl97), resulted in an apparent stabilization of the GRE-AR
complexes (Figure 5). Addition of normal rabbit serum to
reticulocyte lysates or antiserum against AR to a lysate not
containing AR failed to show similar complexes. Competition
with unlabelled GRE of the GRE-AR complex in the presence
of antiserum spi97 was almost complete at a 20-50-fold excess
of unlabelled GRE, confirming the specificity of the observed
complexes (Figure 5).
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Figure 8 (a) Binding of AR synthesized in vitro to 32P-labelled GRE In the
presence of various AR antisera and (b) GRE binding of wild-type and a
mutant AR
(a) Lysate containing AR (2 ,ul) was incubated with 0.1 ,ul of various AR antisera for 2 h at
4 °C and thereafter added to the incubation mixture containing 32P-labelled GRE as described
in the Materials and methods section. Antisera added were: sp197 (lane 1), spO60 (lane 2),
spO63 (lane 3) and spO66 (lane 4) and no antiserum (lane 5). The antisera sp197 and spO6O
are directed against the N-terminal domain, spO63 against the DNA-binding domain and spO66
against the steroid-binding domain of the AR. (b) The AR mutant pAR65 (C602-+S, C605-.S)
was constructed as described and subsequently transcribed and translated in vitro in the same
manner as pARO. Lysates containing ARO protein (lanes 1 and 2) and AR65 protein (lanes 3,
4 and 5) were preincubated with sp197 (lanes 2-4) antiserum or used directly without
incubation with antiserum (lanes 1 and 5). Lysates were added to the incubation mixture
containing 32P-labelled GRE, and protein-DNA complexes were separated from free DNA by
non-denaturing electrophoresis as described in the Materials and methods section. Lanes 1 and
2, 4 #sl of lysate added; lane 3, 2 ,u1 of lysate added; lanes 4 and 5, 4 ,ul of lysate added. The
AR-GRE complex in lane 2 is indicated with an arrow.
After preincubation of the reticulocyte lysate with R1881,
specific GRE-AR complexes could also only be observed in the
presence of AR antiserum spl97 (Figure 6a). The reticulocyte
lysates were pretreated with salt in order to convert the 6 S AR
into the 4 S AR species (see Figure 4). In this case also, GRE-AR
complexes were observed only in the presence of the spi97
antiserum (Figure 6b). The GRE-AR complex can compete with
an ARE from the prostate-specific antigen promotor [25], which
has been shown to confer androgen-responsiveness on a reporter
gene (Figure 7). In contrast, the GRE-AR complex could not
compete with an ERE from the apo-very-low-density lipoprotein
II promotor region [26], confirming the specificity of the GRE-
AR interaction.
In addition to the spl97 antiserum, several other AR antisera
were able to stabilize the GRE-AR complex, although to a lesser
extent (Figure 8a). Interestingly, after preincubation of the
reticulocyte lysate with an antiserum directed against the second
zinc finger of the DNA-binding domain (SP063 antiserum), no
labelled GRE-AR complexes were observed. This confirmed
that the DNA-binding domain ofAR interacts with the labelled
GRE.
The DNA-binding domain of steroid receptors contains two
zinc ions which are tetrahedrally co-ordinated by cysteine resi-
dues. Mutagenesis experiments have shown that these cysteine
residues are essential for DNA-binding capacity [27].
The cysteine residues at positions 602 and 605 in the DNA-
binding domain of the AR protein were mutated to serine
residues, an amino acid that is structurally closely related to
cysteine but which has not been found to co-ordinate zinc ions in
any zinc-containing protein [28]. The mutant obtained (desig-
nated pAR65) was transcribed and translated in vitro. Similar
,lo.
N.
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amounts ofARO and AR65 protein were tested in a gel mobility-
shift assay with labelled GRE (Figure 8b). No AR65-GRE
complexes were observed, showing that AR does indeed interact
via the DNA-binding domain with the GRE, an interaction that
is apparently stabilized by the presence of anti-AR antiserum.
DISCUSSION
The rabbit reticulocyte lysate appears to be a convenient system
for the synthesis ofAR protein. The AR protein produced has a
high binding affinity for androgenic steroids (Kd 0.3 nM) which
is in agreement with previously reported dissociation constants
for human androgen receptors in various cellular systems [29-31].
The difference in apparent molecular mass between the AR
synthesized in vitro (108 kDa) and the AR from LNCaP cells
(110 kDa) is due to a difference in the length of the polyglutamine
stretch in the N-terminus. Various lengths of the human AR
polypeptide, deduced from cDNAs isolated in different labora-
tories, have been reported [13]. The vector pSVARO [23], which
has been used for the construction of the pARO vector, contains
20 glutamine codons, whereas the AR cDNA isolated from the
LNCaP cells contains 27 glutamine codons (J. Trapman and
H. Sleddens, unpublished work). The doublet appearance of the
AR from LNCaP cells (110-112 kDa) is caused by differential
phosphorylation [24]. Alkaline phosphatase treatment ofcytosols
from LNCaP cells caused a gradual elimination of the 112 kDa
isoform, with a concomitant increase in the 110 kDa isoform
[24].
All AR molecules synthesized were able to bind steroid, and
there was no evidence available for AR phosphorylation during
in vitro synthesis. This suggests that AR phosphorylation is not
essential for hormone binding, at least in vitro. This conclusion
is corroborated by the finding that, in LNCaP cells, AR is not
phosphorylated in the DNA- and steroid-binding domains [22].
In contrast, the in vitro synthesized oestrogen receptor binds
oestradiol with high affinity, but low efficiency. Only a kinase
purified from calf uterus was able to convert most of the non-
hormone-binding oestrogen receptor into a steroid-binding state
[18,32].
Other than AR, in vitro synthesized 1,25-dihydroxyvitamin D3
receptor and glucocorticoid receptor were also able to bind
steroid with high affinity without previous phosphorylation by
an exogenous kinase [17,33]. For the in vitro synthesized human
progesterone receptor also, it has been shown that phosphoryl-
ation is not essential for steroid binding [34].
Steroid hormone receptors can be isolated from the cytosol of
target cell extracts as large non-activated 8 S complexes, con-
taining hsp90, hsp70 and p56 [1-2].
In a recent study [2], the hormone-induced transformation of
AR in human prostate carcinoma cells (LNCaP cell line) was
described. On incubation of the cells with R1881 for 30 min at
37 °C, the sedimentation value of the cytosolic AR decreased
from 8 S (non-DNA-binding form of AR) to an intermediate
form of 6 S. The monoclonal antibody F52 (directed against the
DNA-binding domain) specifically recognized the 6 S form of
the AR from LNCaP cells, but not the non-DNA-binding 8 S
AR complex [2]. It appears that the 6 S AR detected in
reticulocyte lysate is similar to the 6 S AR detected in the cytosol
of LNCaP cells after incubation with R1881 at 37 'C. The AR
synthesized in reticulocyte lysate (6 S) can therefore be regarded
as an activated protein. In previous studies, we have shown that
the DNA-binding form of AR in calf uterus cytosol also has a
sedimentation coefficient of 6 S [35], whereas the non-DNA-
binding AR has a sedimentation coefficient of 8 S. In this respect
LNCaP cell nuclear extracts and AR synthesized in vitro (Figure
4b) are all eluted from DNA-cellulose at an NaCl concentration
of 120-140 mM [35] (G. G. J. M. Kuiper, P. E. de Ruiter,
J. Trapman, G. Jenster and A. 0. Brinkmann, unpublished
work).
The composition of the 6 S AR complex in reticulocyte lysate
is at present unknown. It could represent a receptor dimer or a
complex with other proteins such as hsp70. After immunoprecipi-
tation of AR from reticulocyte lysate with F39 antibody and
subsequent immunoblotting with anti-hsp90 and anti-hsp70
antibodies, no signal above background was detected. We
concluded that the amount of AR protein present in reticulocyte
lysate is not sufficient to produce a signal with anti-hsp antibodies
on Western blots. In similar experiments, the 6 S AR complex
from LNCaP cell cytosol was shown to contain hsp70 and
essentially no hsp90 and p56 [2]. The anti-hsp70 antibody we
used (N27 monoclonal antibody from Dr. W. J. Welch, Uni-
versity of California, San Francisco, CA, U.S.A.) does not
recognize the native forms ofthe protein very well. Consequently,
it was not possible to shift the 6 S complex on sucrose density
gradients with N27 antibody, as we did with anti-AR antibodies.
Under similar conditions to those in the present paper, the
glucocorticoid receptor was detected as a 9 S non-DNA-binding
protein [19]. Only after incubation of the in vitro synthesized
glucocorticoid receptor with the agonist dexamethasone and
heat-treatment were receptors able to bind to DNA-cellulose. In
the present investigation it is shown that AR is able to bind to
DNA-cellulose, even in the absence of hormone and heat-
treatment, indicating that it is present as an activated protein.
It is not known at present why the AR in reticulocyte lysate
does not form a stable 8 S complex, despite the presence of
molybdate. Molybdate has been shown to stabilize the 8 S AR
complex in calf uterus cytosol, although its presence is not
essential for the detection of this complex [35]. For the gluco-
corticoid receptor in reticulocyte lysates, it has been shown that
hsp9o is necessary but not in itself sufficient for the formation of
the non-activated (non-DNA-binding) receptor complex [36].
Other components might be needed for the formation of the 8 S
AR complex which are either not present at all in the reticulocyte
lysate or not in sufficient amounts.
The human AR synthesized in vitro displays specific binding to
target DNA sequences as shown using the gel mobility-shift
assay. The complexes formed are DNA-sequence-specific, as
they form in the presence of high concentrations of poly(dI-
dC) poly(dI-dC) and can compete with low molar ratios of
GRE/ARE sequences but not an unrelated ERE sequence.
However, the affinity for these responsive elements is rather low.
Only in the presence of specific AR antisera can stable complexes
be detected. This is the case for the 4 S AR protein as well as for
the 6 S AR complex (Figure 6). Such a stabilization has also been
described in mobility-shift assays with antibodies directed against
the progesterone receptor [37], and more recently also for
complexes formed between a fragment ofAR expressed in E. coli
and ARE/GRE oligonucleotides [38]. Steroid hormone receptors
can bind as symmetrical dimers to palindromic steroid responsive
elements [27]. The stabilization of the AR-GRE complex in the
presence ofAR antisera could be explained by antibody-induced
AR dimerization with the result that high-affinity DNA binding
is achieved. For the in vitro synthesized mouse oestrogen receptor,
it has been shown that there is a direct correlation between
specific DNA binding and dimerization [39].
Another explanation, other than the absence of AR dimeri-
zation, for the low-affinity DNA binding might be that AR-
associated proteins enhancing the interaction ofAR protein and
it is interesting to note that AR from calf uterus cytosol and DNA are nussing from the present system. There is strong
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evidence available suggesting that receptors interact with other
factors involved in transcriptional regulation and that such
protein-protein contacts might increase the affinity of receptors
for responsive elements [40-43]. The present system, involving
AR synthesized in reticulocyte lysate, could serve as a valuable
probe in measuring and isolating such putative factor(s) from
nuclear extracts of target cells.
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